Buy Jyseleca - available now at insulinhub.com
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufacturer for Europe
Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland
Information about Jyseleca (Filgotinib)
Jyseleca is an oral Janus kinase (JAK) inhibitor indicated for the treatment of moderate to severe rheumatoid arthritis. It selectively targets JAK1, which plays a key role in the inflammatory process associated with autoimmune diseases.
Product Highlights
Treatment of adults with moderate to severe rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).
Key Ingredient
Key Benefits
- Demonstrated significant improvements in symptoms of rheumatoid arthritis, including joint pain and swelling.
- Once-daily dosing enhances adherence to treatment.
- Targets JAK1 specifically, which may result in fewer side effects compared to non-selective JAK inhibitors.
Direction of Use
- Take Jyseleca exactly as prescribed by your healthcare provider, usually once daily.
- It can be consumed with or without a meal.
- Do not exceed the prescribed dose and consult your doctor if a dose is missed.
Safety Concerns
- Common side effects include nausea, headaches, and a higher risk of infections.
- Serious side effects can include blood clots, liver enzyme elevation, and changes in blood cell counts.
- Regular monitoring may be required to assess liver function and blood parameters.
Avoid Jyseleca (Filgotinib) If
- You have a known hypersensitivity to filgotinib or any of its components.
- You have active or serious infections.
- You have severe liver impairment.
- You are taking medications that may interact adversely with filgotinib.
